Similar results were reported in two clinical trials involving patients with relapsing remitting multiple sclerosis (RRMS) that RTX led to a >95 ​% reduction of CD19+ peripheral B cells within two weeks after the last infusion [33,34]. This evidence concerns the gene CD19 and relapsing-remitting multiple sclerosis.